Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Olaparib

Stage Phase 2

Sponsor Hospices Civils de Lyon (OLAGLI)

Route oral

Modality small molecule

Class PARP inhibitor

Target PARP1/2

Sources

publication, as of 2026-11-07

https://pmc.ncbi.nlm.nih.gov/articles/PMC11157627/

OLAGLI: olaparib in recurrent IDH-mutant high-grade glioma, POLA Network Phase 2 (NCT03561870), PMC11157627 (search record)

Brief source I14

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03561870

A Phase II Study of Olaparib in Recurrent IDH-mutant High Grade Gliomas OLAGLI

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03991832

A Phase II Study of Olaparib and Durvalumab (MEDI 4736) in Patients With IDH-Mutated Solid Tumors

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05188508

A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients With Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

OLAGLI

Registry NCT03561870

Phase Phase 2

Status Completed

Enrollment 35

Start 2019-03-20

Primary completion 2021-11-08

Study completion 2021-11-24

Olaparib 300 mg BID

Dose 300 mg

Regimen twice daily

Population recurrent IDH-mutant high-grade glioma (n = 35)

Estimand Single arm

6-month PFS rate: 31.4%, primary endpoint, target 50% not met

median PFS: 2.05 months

median OS: 15.9 months

SOLID (olaparib + durvalumab)

Registry NCT03991832

Phase Phase 2

Status Active, not recruiting

Enrollment 58

Start 2019-12-31

Primary completion 2026-09-30

Study completion 2026-09-30

Catalyst Primary completion. 09.30.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

NCT05188508

Registry NCT05188508

Phase Phase 2

Status Recruiting

Enrollment 57

Start 2022-01-14

Primary completion 2027-01

Study completion 2027-01

Catalyst Primary completion. 01.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.